Phase 2 Myeloma Trial, Recruiting NCT06581640 Sponsor: The First Affiliated Hospital of Xiamen University Condition: Myeloma
Back to Myeloma

Phase 2 Myeloma Trial, Recruiting

NCT06581640
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are between 18 and 80 years old (any gender)
  • You have been diagnosed with multiple myeloma that has come back or has not responded to previous treatments
  • Lab or tissue tests show that your myeloma cells have a protein called BCMA on their surface
  • Your doctor estimates you are expected to live longer than 3 months
  • You are reasonably active and able to care for yourself (not completely disabled by your illness)
  • Your liver, kidneys, heart, and lungs are working well enough to meet specific medical standards (confirm with trial site)
  • Your blood counts meet certain minimum levels, and you have a suitable vein for collecting blood cells (confirm with trial site)
  • If you are able to have children, you must agree to use reliable contraception during the trial
  • You (or your legal guardian) are willing and able to understand and sign a consent form

Who may not be able to join:

  • You are pregnant, breastfeeding, or planning to become pregnant within the next six months
  • You have tested positive for hepatitis B, hepatitis C, HIV, syphilis, or cytomegalovirus
  • You have a history of another type of cancer (with exceptions for certain fully treated skin or cervical cancers with no signs of return — confirm with trial site)
  • You have previously received a treatment that specifically targeted the BCMA protein
  • You had a stem cell transplant using your own cells within the last 6 weeks
  • You currently have a bacterial or fungal infection that is not under control
  • You are allergic to any of the drugs or cell components used in this trial
  • You have an active autoimmune disease (where your immune system attacks your own body)
  • You currently have unstable ulcers or active bleeding in your stomach or digestive system
  • You have a mental health or psychological condition that would make it difficult to participate in the treatment and assessments
  • You have taken part in another experimental drug trial within the last 3 months
  • The trial doctor feels there are other reasons you would not be suitable for this trial (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Bing Xu, The First Aiffiliated hosptical of xiamen University

Phone: 18750918842

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
The First Affiliated Hospital of Xiamen University
Registry
ClinicalTrials.gov
Start date
24 September 2024
Est. completion
31 December 2028

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Complete remission rate (CR)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov